WO2005075646A1 - ストレス誘導抗アポトーシス分子(iex−1)由来ペプチド - Google Patents
ストレス誘導抗アポトーシス分子(iex−1)由来ペプチド Download PDFInfo
- Publication number
- WO2005075646A1 WO2005075646A1 PCT/JP2005/001508 JP2005001508W WO2005075646A1 WO 2005075646 A1 WO2005075646 A1 WO 2005075646A1 JP 2005001508 W JP2005001508 W JP 2005001508W WO 2005075646 A1 WO2005075646 A1 WO 2005075646A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- hla
- ctl
- cells
- iex
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 211
- 230000006909 anti-apoptosis Effects 0.000 title description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 72
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 72
- 108010026122 HLA-A*33 antigen Proteins 0.000 claims abstract description 43
- 229920001184 polypeptide Polymers 0.000 claims abstract description 34
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 17
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 16
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 16
- 230000001939 inductive effect Effects 0.000 claims abstract description 15
- 238000009566 cancer vaccine Methods 0.000 claims abstract description 12
- 229940022399 cancer vaccine Drugs 0.000 claims abstract description 12
- 101000999079 Homo sapiens Radiation-inducible immediate-early gene IEX-1 Proteins 0.000 claims abstract 2
- 102100036900 Radiation-inducible immediate-early gene IEX-1 Human genes 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 106
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 125000000539 amino acid group Chemical group 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 7
- 230000001472 cytotoxic effect Effects 0.000 claims description 6
- 230000002424 anti-apoptotic effect Effects 0.000 claims description 5
- 231100000433 cytotoxic Toxicity 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 70
- 108090000623 proteins and genes Proteins 0.000 abstract description 37
- 201000011510 cancer Diseases 0.000 abstract description 34
- 230000006907 apoptotic process Effects 0.000 abstract description 4
- 239000000203 mixture Substances 0.000 abstract description 3
- 108091007433 antigens Proteins 0.000 description 30
- 239000000427 antigen Substances 0.000 description 29
- 102000036639 antigens Human genes 0.000 description 29
- 230000014509 gene expression Effects 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 22
- 101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 description 20
- 102100037850 Interferon gamma Human genes 0.000 description 19
- 108010074328 Interferon-gamma Proteins 0.000 description 19
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 230000000890 antigenic effect Effects 0.000 description 18
- 108010075704 HLA-A Antigens Proteins 0.000 description 17
- 102000011786 HLA-A Antigens Human genes 0.000 description 17
- 238000004519 manufacturing process Methods 0.000 description 17
- 208000005718 Stomach Neoplasms Diseases 0.000 description 14
- 206010017758 gastric cancer Diseases 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 201000011549 stomach cancer Diseases 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 13
- 230000027455 binding Effects 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 230000003013 cytotoxicity Effects 0.000 description 11
- 231100000135 cytotoxicity Toxicity 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000009169 immunotherapy Methods 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 10
- 239000013642 negative control Substances 0.000 description 8
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 108700028369 Alleles Proteins 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 6
- 230000035882 stress Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 229940023041 peptide vaccine Drugs 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 238000001400 expression cloning Methods 0.000 description 4
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 3
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 239000012124 Opti-MEM Substances 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 101150084750 1 gene Proteins 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 101710101924 Endo-1,4-beta-xylanase 1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 1
- 108010086377 HLA-A3 Antigen Proteins 0.000 description 1
- 101001128500 Homo sapiens Marginal zone B- and B1-cell-specific protein Proteins 0.000 description 1
- 101000735539 Homo sapiens Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 description 1
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100113084 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mcs2 gene Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 241000251131 Sphyrna Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000000158 apoptosis inhibitor Substances 0.000 description 1
- -1 aromatic amino acids Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 108010048032 cyclophilin B Proteins 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 108010051081 dopachrome isomerase Proteins 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 102000055955 human ADCYAP1 Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 229940125667 peptide vaccine candidate Drugs 0.000 description 1
- 108010044156 peptidyl-prolyl cis-trans isomerase b Proteins 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- UFTCZKMBJOPXDM-XXFCQBPRSA-N pituitary adenylate cyclase-activating polypeptide Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 UFTCZKMBJOPXDM-XXFCQBPRSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000020129 regulation of cell death Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a peptide derived from a stress-induced anti-apoptotic molecule (IEX-1) that can be used in immunotherapy for cancer patients.
- IEX-1 a stress-induced anti-apoptotic molecule
- the present invention relates to an IEX-1-derived peptide that is recognized by cytotoxic T cells (CTL) and induces a specific CTL, a polypeptide containing the peptide, a cancer vaccine containing these peptides, and the like.
- Gastric cancer is one of the most universally occurring malignant tumors in the world (References 16).
- the disease has a generally good prognosis at an early stage, but in advanced cancer, despite the recent significant advances in existing therapies such as surgical resection, chemotherapy, and radiation therapy, Prognosis is very bad. Therefore, there is a need to develop new therapies such as new specific immunotherapy to treat patients with advanced stage gastric cancer.
- IEX-1 immediate early response gene Xl
- PRGl PRGl
- Dif-2 ref. 21
- mouse homolog gyl96 mouse homolog gyl96
- IEX-1 expression is rapidly activated by several cellular stresses including irradiation, growth factors, viral infections, inflammatory site forces such as TNF- ⁇ and IL 1 ⁇ , lipopolysaccharides, and steroid hormones. It can be activated (Reference 27).
- ⁇ -1 was originally identified as a ⁇ F- ⁇ BZrel target gene (Reference 23), but the IEX-1 promoter includes consensus sequences for other transcription factors such as p53, SP-1 and c Myc. Some are included (Reference 7). For example, it has been shown that the expression of a tumor suppressor gene p53 common to tumor cells increases the expression of EX-1 (Reference 29).
- IEX-1 has been suggested to be involved in malignant transformation of tumor cells.
- No IEX-1 epitope peptide has been known to function as an antigenic peptide in tumor cells. .
- An object of the present invention is to provide an antigenic peptide useful for developing a cancer vaccine for HLA-A33 + cancer patients.
- the present inventors also established the HLA-A33-restricted CTL line in tumor tissue infiltrating lymphocyte (TIL) in patients with severe gastric cancer, and obtained three HLA-A33 binding epitopes derived from IEX-1 Identified as a tumor antigen recognized by the cell line. Furthermore, the present invention was completed by confirming that these antigenic epitopes induce peptide-specific CTLs in PBMC (peripheral blood mononuclear cells) of patients with malignant tumor diseases.
- TIL tumor tissue infiltrating lymphocyte
- the present invention includes the following.
- IEX-1 stress-induced anti-apoptotic molecule
- CTL cytotoxic T cells
- the peptide having the amino acid sequence ability shown in any one of SEQ ID NOS: 1 to 3 or the amino acid sequence shown in the SEQ ID NO: 1 to 3 is missing one or more amino acids, (1)
- a polypeptide comprising the peptide according to any one of (1) to (4) above.
- Antigen presentation by presenting a complex of the HLA-A33 molecule and (1) one (4) of any of the peptides described in (4) above on the surface of the isolated antigen-presenting cell. cell.
- a pharmaceutical composition for inducing specific CTL comprising the polypeptide according to 1) or 2) below:
- the present invention enables IEX-1-based immunotherapy suitable for the treatment of malignant tumors, particularly HLA-A33 positive cancer patients.
- FIG. 1 Characteristics of HLA-A33-restricted 850B-CTL cell line established from tumor-infiltrating live lymphocytes (TIL) of gastric adenocarcinoma patients (HLA—A * 2402ZA * 3303, B7 / B44, Cw7ZCwl4)
- TIL tumor-infiltrating live lymphocytes
- FIG. A shows the result of examining the recognition ability for various target cells based on the production of IFN ⁇ in various E: T ratios (one cell: target cell).
- ⁇ shows the results of a 6-hour 51 Cr release test for cytotoxic activity against various target cells at different ⁇ : ⁇ ratios.
- C is a graph showing the difference in reactivity of 850B-CTL to HLA-A33 + LC-1 cells in inhibition experiments using various mAbs.
- FIG. 2 is a diagram showing HLA-A33-restricted recognition of an identified tumor antigen gene by the 850B-CTL cell line.
- LC 1 Lung adenocarcinoma cell cDNA library IFN- ⁇ shows the reactivity of 850B-CTL to COS7 cells that have been cloned together with clones obtained by the gene expression cloning method and HLA-A3303 or HLA-A2601 gene.
- Tests B and J were performed based on production.
- FIG. 3 shows the expression of IEX-1 at the mRNA and protein level.
- A is a reproduction of photographs showing the results of examining the expression of IEX-lmRNA in various normal tissues by Northern plot analysis using a 32 P-labeled IEX-1 probe.
- B is a copy of a photograph showing photoradiography in Northern blot analysis of IEX-1 gene mRNA expression in normal and cancer cells.
- C-E is a photomicrograph showing the results of immunohistochemical examination of the expression of IEX-1 in various tumor tissues at the protein level.
- C shows staining in stomach cancer tissue
- D shows breast cancer
- E shows lung cancer
- FIG. 4 is a diagram showing identification of antigenic epitopes in IEX-1. Eight candidate peptides that could have strong binding activity against HLA-A33 were selected and tested by computer analysis based on the HLA-A33 binding motif of the deduced amino acid sequence of IEX-1. A these are 8 After culturing these candidate peptides with C1R-A33 cells (C1R human multiple myeloma cells stably transfected with HLA-A * 3303 cDNA) and then adding 850B-CTL The results of measuring IFN ⁇ production in the culture supernatant by ELISA are shown.
- C1R-A33 cells C1R human multiple myeloma cells stably transfected with HLA-A * 3303 cDNA
- ⁇ is the concentration of the three peptides ( ⁇ 47-56, IEX61-69, and ⁇ 65-73 peptides) that induced significant levels of IFN- ⁇ production and one control peptide, and ⁇ -1 reactive CTL-inducing activity. The result of examining the relationship is shown.
- FIG. 5 shows a cellular response to peptides. 147-56, IEX61-69, and ⁇ 65-73 peptides stimulated ⁇ MC in HLA- ⁇ 33 + epithelial cancer patients and HLA- ⁇ 33 + healthy subjects and pulsed with the corresponding peptide C1R— ⁇ 33 cells or negative control HI Stimulation was performed with C1R-A33 cells pulsed with V-peptide and cell responses were tested based on IFN- ⁇ production activity.
- FIG. 6 shows the cytotoxicity of peptide-induced CTL.
- LC-1 HLA-A33 + IE X— 1+
- QG56 HLA— ⁇ 33— ⁇ —1 +
- HGC27 HLA— ⁇ 33— ⁇ — ⁇
- FIG. 7 shows the results of a cytotoxicity inhibition test using a monoclonal antibody.
- Peptide stimulation using anti-HLA class I, anti-HLA class II, anti-CD8 (Nu—TsZc, IgG2a), anti-CD4 (Nu—ThZi, IgGl) and anti-CD14 (JML—H14, IgG2a) mAb as controls The inhibitory effect of PBMC on cytotoxicity was examined.
- the HLA-restricted CTL line infiltrates the tumor tissue of cancer patients with the target HLA allele, collects lymphocytes (TIL), and cultures them with IL-2, a site force-in that promotes T cell proliferation. Obtained by proliferation.
- TIL lymphocytes
- IL-2 a site force-in that promotes T cell proliferation. Obtained by proliferation.
- Tumor antigens recognized by HLA-restricted CTL lines are identified by gene expression cloning.
- the protein encoded by the cDNA library is transiently expressed in mammalian cells, the cDNA that encodes the protein of interest specifically recognized by the established CTL line is screened, and the protein is encoded.
- the gene to be isolated is isolated.
- screening is performed using IFN- ⁇ produced when an established CTL line recognizes a protein-expressing cell as an index.
- the peptide derived from IEX-1 of the present invention is a peptide capable of inducing specific CTL by binding to HLA.
- the peptide of the present invention preferably has a force of 8 to 11 consecutive amino acid residues of IEX-1.
- Specific examples of such a partial peptide of IEX-1 include IEX47-56, (SEQ ID NO: 1), IEX61-69 (SEQ ID NO: 2), or IEX65-73 (SEQ ID NO: 3).
- the complete nucleotide sequence of IEX-1 gene and the deduced amino acid sequence are registered under GeneBank as accession number NM-003897 (SEQ ID NO: 4).
- Other IEX-1-derived peptides that induce specific CTLs can be easily determined and selected by a method according to the examples of the present specification.
- the phrase “can bind to HLA and induce specific CTL” means that the peptide of the present invention binds to HLA to form a complex, and CTL can recognize the complex formed. .
- the peptide of the present invention has a binding activity to HLA and an activity to induce peptide-specific CTL in the form of a complex with HLA.
- the preferred HLA for the present invention is HLA-A33.
- the present invention also includes a mutant peptide of an IEX-1-derived peptide capable of inducing specific CTLs by binding to HLA, and having a similar CTL inducing ability.
- the mutation can be introduced by deleting, replacing, adding, or inserting one or several amino acids into the IEX-1-derived peptide of the present invention, and its means is well known in the art. It is.
- the mutation includes substitutions or additions with other amino acids, the other amino acids may be natural amino acids or amino acid analogs.
- amino acid analogs various amino acid N-acylates, O-acylates, Esterified product, acid amidated product, alkylated product Etc.
- one or more of the amino acid sequences shown in SEQ ID NOs: 1 to 1, preferably 1 to 4, more preferably 1 to 3, more preferably Ability to delete one or two amino acid residues A candidate peptide substituted with or added with another amino acid residue or amino acid analog is synthesized, and the candidate peptide and HLA-A33 are synthesized. It can be identified by assessing whether the complex with the molecule is recognized by CTL.
- the assembly can be performed according to the CTL induction method described later. That is, when a candidate peptide is added and stimulated in vitro, it is examined whether or not CTL that specifically recognizes HLA-A33 positive cells pulsed with the candidate peptide can be induced.
- the presence or absence of CTL induction is determined, for example, by measuring the amount of various site force ins (such as IFN-y) produced by CTL in response to antigen peptide-presenting cells by enzyme immunoassay (ELISA) or the like. Can be studied. Alternatively, it can also be examined by a method of measuring the damage of CTL to 51 Cr-labeled antigen peptide-presenting cells ( 51 Cr Release Atsey, Int. J. Cancer, 58: p317,1994). Examples of the HLA-A33 positive cells used in the above assay include the HLA-A33 positive cells described in Examples.
- the number of amino acid residues of the mutant peptide is usually at least about 8 or more, preferably about 9 or more, as long as it is a number that is displayed on the surface of the antigen-presenting cell and has a property as a CTL-recognizing epitope. Thus, it is 12 or less, preferably 11 or less, more preferably 10 or less. Particularly preferred are 9 and 10 amino acid residues.
- the present invention further includes a polypeptide containing the IEX-1-derived peptide of the present invention or a mutant peptide thereof having specific CTL inducing activity.
- the number of amino acids constituting the polypeptide is not particularly limited, and follows the common general technical knowledge in the field to which the present invention belongs. Usually, the length is about 100 or less amino acid residues, preferably about 50 or less, more preferably about 30 or less.
- polypeptide of the present invention can be fragmented in HLA-A33-positive cells to give a peptide fragment having specific CTL inducing activity.
- a polypeptide contains a partial sequence corresponding to the peptide of the present invention represented by SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3, or a sequence corresponding to a variant of the peptide of the present invention. Is particularly preferred.
- the peptides and polypeptides of the present invention can also be modified by modifying the constituent amino acids or carboxyl groups to the extent that the function is not significantly impaired.
- the N-terminus or free amino group may be bound to a formyl group, acetyl group, t-butoxycarbol (t Boc) group, etc.
- t Boc t-butoxycarbol
- a methyl group, an ethyl group, a t-butyl group, a benzyl group or the like may be bonded.
- the peptide of the present invention may be modified so as to facilitate introduction into the living body.
- motifs regular sequences depending on the type of HLA in the amino acid sequence of tumor antigen peptides that bind to HLA molecules. It is preferable that From the viewpoint of not changing the basic properties (physical properties, functions, physiological activities, immunological activities, etc.) of peptides or polypeptides in the introduction of mutations, for example, homologous amino acids (polar amino acids, nonpolar amino acids, Mutual substitution between hydrophobic amino acids, hydrophilic amino acids, positively charged amino acids, negatively charged amino acids and aromatic amino acids is easily envisaged.
- the peptides and polypeptides of the present invention can be produced by general known methods in peptide science.
- Antigen-presenting cell means a cell that presents a complex of HLA and an antigen peptide on the cell surface. Accordingly, the antigen-presenting cell has a function of bringing about the activity of HLA-A33-restricted CTL by presenting the complex of the tumor antigen peptide of the present invention and the HLA A33 molecule on the cell surface. Such cells also include tumor cells that are targets for CTL cytotoxic effects.
- the antigen-presenting cell of the present invention presents a complex of the HLA A33 molecule and the tumor antigen peptide of the present invention on the surface of an isolated cell having antigen-presenting ability.
- Such cells can also be induced in vitro. Specifically, cells having HLA-A33-positive antigen-presenting ability are pulsed with the tumor antigen peptide of the present invention, and HLA-A33 and the peptide can be induced.
- This complex is obtained by presenting the complex on the cell surface.
- the “cell having antigen-presenting ability” is not particularly limited as long as it expresses on the cell surface the HLA-A24 antigen capable of presenting the tumor antigen peptide of the present invention. High, supposed rod cells Is preferred.
- antigen-presenting cells in which a complex of an HLA-A33 molecule and the tumor antigen peptide of the present invention is presented on the surface of an isolated antigen-presenting cell derived from an HLA-A33-positive tumor patient I like it.
- the nucleic acid molecule of the present invention includes single-stranded (including complementary strands) and double-stranded polynucleotides encoding the amino acid sequence of the IEX-1-derived peptide of the present invention or a mutant peptide thereof and a polypeptide containing the peptide. including.
- the nucleic acid molecule of the present invention may be DNA or RNA. Peptides having the amino acid sequences encoded by these nucleic acid molecules are recognized by CTLs themselves and can provide peptides that activate the CTLs and peptide fragments having such activities as tumor antigens. Can function.
- the nucleic acid molecule of the present invention may be a polynucleotide having a base strength of at least 24 corresponding to the region encoding the peptide of the present invention and its complementary strand.
- a polynucleotide can be selected, for example, by confirming the expressed peptide using a known protein expression system.
- the antibody of the present invention may be a deviation from a monoclonal antibody or a polyclonal antibody.
- a peptide or polypeptide consisting of at least 5 consecutive amino acid residues in the amino acid sequence of one peptide or polypeptide that is also selected for the IEX-1 derived peptide or polypeptide of the present invention is specifically selected. It is something to recognize.
- Antibodies can be generated using these epitope peptides, which are composed of at least 5, preferably at least 8-10 amino acids.
- the present invention also includes a peptide having at least 5 amino acid residues and a nucleic acid molecule encoding the same.
- the antibody of the present invention can induce production by immunizing, for example, mice, rats, rabbits, goats, etc. in the presence or absence of adjuvant, in the presence or absence of an epitope peptide alone or in a form bound to a carrier. it can.
- the obtained polyclonal antibody can be recovered from the serum by a known method.
- Antibody-producing cells can be produced by fusing with permanently proliferating cells. This method is well known in the art.
- polyclonal and monoclonal antibodies can be used as purification antibodies, reagents, labeling markers, and the like. In addition, it may be humanized and used for treatment.
- the pharmaceutical composition of the present invention is an antigen-presenting cell, peptide or polypeptide obtained by presenting the IEX-1-derived peptide, mutant peptide, polypeptide, or HLA molecule-peptide complex of the present invention on the cell surface.
- the IEX-1-derived peptide of the present invention or a variant thereof, a polypeptide containing the peptide, and antigen-presenting cells can be used as a cancer vaccine.
- the ability to use even one type of peptide as a cancer vaccine It is preferable to use a combination of multiple types of peptides. This is because the CTL of cancer patients is a population of cells that recognize multiple different types of tumor antigens, so it is expected that it will be more effective to use multiple types of tumor antigens in combination as a cancer vaccine. This is because that.
- a plurality of the peptides according to the present invention may be used in combination with other peptides.
- the cancer vaccine of the present invention can be used alone or in combination with a pharmaceutically acceptable carrier in the presence or absence of a suitable adjuvant.
- the carrier is not limited as long as it does not adversely affect the human body.
- cellulose, polymerized amino acid, albumin and the like can be used.
- As the dosage form a known dosage form for peptide preparations can be selected. The dosage varies depending on the recognition by CTL, the disease to be treated, the patient's age, weight, etc.
- the active substance is usually O.OOOlmg—1000 mg, preferably O.OOlmg—1000 mg.
- O.lmg-100 mg Preferably O.lmg-100 mg, more preferably 0.1-10 mg / day Z adult human. This is administered once every few days or several weeks or months.
- the pharmaceutical composition of the present invention can also be used to incorporate a nucleic acid sequence encoding the peptide of the present invention into an appropriate vector and introduce it in vivo or ex vivo.
- a vector for example, a force retrovirus system including retrovirus, adenovirus, vaccinia virus and the like is preferable.
- the dose is 0.1 ⁇ g-100 mg / day Z adult human, preferably 1 ⁇ g-50 mg Z day Z adult human, as the 1S DNA content varies depending on the recognition by CTL. This is administered once every few days or months.
- IEX-1 reactive CTL means a CTL induced by recognizing a complex of an IEX-1 derived peptide of the present invention or a variant thereof and HLA.
- the CTL is HLA-A33-restricted CTL.
- Such CTLs can be derived, for example, from peripheral blood mononuclear cells (PBMC) of HLA-A33 + gastric cancer patients using the peptides according to the present invention.
- PBMC peripheral blood mononuclear cells
- CTL is induced by incubating PBMCs of HLA-A33 + gastric cancer patients with antigen-presenting cells (APC) pulsed with the peptide of the present invention, and evaluated using IFN- ⁇ production as an index. Furthermore, the activity of induced CTL can be confirmed by tumor cell toxicity as an index by 51 Cr release test or the like.
- APC antigen-presenting cells
- the above-described method can be used for adoptive immunotherapy in which antigen-specific CTLs induced in vitro are returned to the body of a patient to injure tumor cells.
- adoptive immunotherapy in which the patient's own tumor-infiltrating T cells are cultured in large quantities outside the body and then returned to the patient (J. Natl. Cancer. Inst., 86 : 1159, 1994).
- mouse melanoma spleen cells are stimulated in vitro with tumor antigen peptide TRP-2, CTLs specific for tumor antigen peptides are propagated, and the CTLs are administered to melanoma-transplanted mice.
- the tumor antigen peptide of the present invention can be used to stimulate a patient's peripheral blood lymphocytes in vitro to increase tumor-specific CTL, and then return the CTL to the patient to treat the tumor.
- Example [0026] The following cancer cell lines were used in the present invention.
- the HLA class I genotypes of these tumor cells have been shown previously (10, 11).
- HLA class I or HLA- ⁇ 33 antigen on these cells is determined by anti-HLA class I (W 6 ⁇ 32) monoclonal antibody (mAb) (recognizing a single region of the HLA class I molecule), or anti-HLA-A33 mAb ( Recognized by flow cytometry on a FACScan (Becton Dickinson, San Jose, Calif.) Using (recognizing the polymorphic region of the HLA-A33 molecule) (IgM, One Lamda, Canoga Park, Calif.).
- mAb monoclonal antibody
- FACScan Becton Dickinson, San Jose, Calif.
- HLA-A33-restricted and tumor-specific CLT strain is a 10% FCS (Equitech Bio, Ingram) for TIL of patients with severe gastric adenocarcinoma (HLA—A * 2402ZA * 3303, B7 / B44, Cw7 / Cwl4) , TX), 100U, mllL-2 (Shionogi Pharmaceutical, Osaka, Japan), and 10 / z gZmlPHA Difco, Detroit, MI) containing culture media (45% RPIM16 40 media, 45% AIM—V media; Life Technologies, Walkersville , MA) for 14 days, followed by further culturing for more than 30 days in the presence of irradiated (30 Gy) allogenic peripheral blood mononuclear cells (PBMC) as support cells.
- PBMC peripheral blood mononuclear cells
- the phenotype of this CTL line was examined by immunological fluorescence test using FITC-conjugated anti-CD3, CD4, or CD8 monoclonal antibody (mAb) and found to be CD3 + CD4—CD8 + (> 95%) (data not shown) Presentation).
- 850B-CTL showed stronger cytotoxicity against HLA—A33 + LC—1 and KUMA—1 cells, but provided HLA—A33—target cell, COS7 cell, NK target cell line, K562, or healthy HLA— H33 + ⁇ activated normal T cells (PHA immature cells) obtained from the PBMCs of the elderly were not shown.
- Anti-HL A class I W6Z32, IgG2a
- anti-CD8 Nu-Ts / c, IgG2a
- anti-HLA—A24 0041 HA, IgG2a
- anti-CD4 Nu-Th / i, IgGl
- anti-HLA class IB C (Bl-23, IgG2a)
- anti-HLA class II H-DR, IgG2a) mAb (20 ⁇ g / ml) were used in the same manner as described in the literature (10, 11).
- Anti-CD14 JML—H14, IgGl
- anti-CD13 MCS2, IgG2a
- IFN— ⁇ production from 850B—CTL by recognition of HLA—A33 T LC—1 cell was inhibited by anti-HL ⁇ class I and anti-CD8 mAb (20 ⁇ g / ml).
- the gene encoding the tumor antigen recognized by the 850B-CTL strain was identified by the gene expression cloning method (Reference 9).
- RNA from LC-1 lung adenocarcinoma cells was converted to cDNA, Sail adapters were ligated and inserted into the expression vector pSV—SPORT-6 (Invitrogen, San Diego, Calif.).
- HLA—A * 3303 or HLA—A * 2601 cDNA is KUMA—1 or KE, respectively.
- RNA force recovered from 4 cells was prepared by RT-PCR, inserted into a eukaryotic cell expression vector pCR 3 (Invitrogen) and cloned.
- LC—lcDNA library plasmid DNA pool or clone (200 ng) and HLA—A * 3303 or HLA—A * 2601 (negative control) cDNA (200 ng) were combined with 1 ⁇ l of lipofucamine (Invitrogen). Mix in 120 ⁇ l Opti-MEM (Invitrogen) for 40 minutes. COS7 cells (5xl0 3) The mixture was incubated 50 mu 1 and 6 hours, followed by 10% FCS-containing RPMI1640 medium 0.99 mu 1 was added Caro.
- the primary screening all lxlO 5 clones obtained from the LC-lcDNA library were transfected into COS7 cells with HLA-A * 3303 cDNA, and then stimulated IFN- ⁇ production by 850B-CTL. Tested for ability. That is, the cDNA pool (lxlO 5 clones) was duplicated into approximately 2000 different wells in 96 flat-bottom plates (expected number of clones for each well: 100 clones Z-well). The primary screening yielded significant levels of IFN- ⁇ production in 10 different wells. As a secondary screen, each cDNA pool obtained by cloning from positive wells was divided into about 200 different wells on 96 flat-bottom plates in duplicate and tested for IFN- ⁇ production stimulating activity.
- DNA sequencing was performed by the dideoxynucleotide sequencing method using DN A sequence kit and ABI PRISM 377 DNA sequencer (Perkin-Elmer, Foster, CA). For one of the isolated genes!
- COS7 cells transfected with clone 1 and HLA—A * 3303 induced clones of clone 1 as a force-negative control that induced IFN- ⁇ production in 850B-CTL in a dose-dependent manner.
- HLA- ⁇ * 2601 transfected cells did not induce.
- COS7 cells transfected with either clone 1 or HLA -— * 3303 alone were not recognized by 850B-CTL (data not shown).
- other clones used as negative controls that also gained the full LC-lcDNA library include HLA-A * 3303 Both were unable to induce IFN- ⁇ production in 850B-CTL when transferred to COS7 cells (data not shown). This suggests that clone 1 encodes a tumor antigen that is specifically recognized by 850 ⁇ -CTL.
- a GeneBank search revealed that the nucleotide sequence of clone 1 was identical to the sequence of IEX-1 (Reference 17) reported as a stress-induced anti-apoptosis gene o
- a band of approximately 1.3 kb was clearly detected in all normal tissues tested except the brain (lane 1), and the heart (lane 2), kidney (lane 7), and lung (lane 11).
- PBL peripheral blood lymphocytes
- HCG27 gastric cancer cell line (lane 5), the stomach (lanes 2-4, 12), lungs (lanes 6, 7), head and neck (lane 8), spleen (lane 9), and colon ( It was highly expressed in most test adenocarcinoma and SCC cell lines derived from various organs including lanes 10 and 11).
- FIG. 3C IEX-1 protein expression was selectively enhanced in cancer cells, but not in surrounding normal epithelium or connective tissue. IEX-1 protein is also highly and selectively expressed in various types of cancer tissues, including breast cancer ( Figure 3D), lung cancer ( Figure 3E), and colon cancer (data not shown). It was. In FIG. 3C-E, IEX-1 protein is stained brown, and normal cells and connective tissue are not stained brown. These brown spots are indicated by arrows for convenience.
- IEX-1 is one of the ideal target molecules for cancer treatment.
- RMA—S— ⁇ 33 cells HLA—A * 3303 cDNA stably transferred RMA—S tap (transporter involved in peptide processing) -deficient mouse lymph 1 £ Takedatsu, et ai., Identification of Peptide Vaccine and anmdates Sharing Among HLA—A3, -Al l, —A31, and -A33 Cancer Patients., Clin Can Res, 2004, in press) (lxlO 4 cell Z-tool) Briefly, cells were incubated for 18 hours at 26 ° C.
- C1R A33 cells for detection of antigenic peptides recognized by the 850B-CTL line
- HLA-A * 3303 cDNA was stably transferred to C1R human multiple myeloma cells (Hiroko Takedatsu, et al., Clin Can Res, 2004, in press) with the indicated concentration of peptide. after cultured. two hours, 850B- added CTL (2xl0 5 cells / Ueru), 18 hours were incubated further. the production of IFN-gamma in the culture supernatant was measured by ELISA.
- HLA— ⁇ 33 transformer The optimal concentration of the three peptides to load on the fetal C1R cells varied from 0.1 to 1 ⁇ for each peptide (Fig. 4 ⁇ ), but the RMA- S ⁇ 33 cells The determined HLA — ⁇ 33 molecules did not depend on their binding affinity (Table 1).
- HLA- ⁇ 33 + cancer patients and HLA- ⁇ 33 + healthy people PBMC (1 ⁇ 10 5 uel) were incubated with each peptide (10 M) in IL 2-containing culture medium 200 1 in 96-well microculture plates (Nunc, Roskiide, Denmark) (Reference 13).
- the peptide-stimulated PBMC 80-120xl0 4 Z well was collected, washed and divided into 4 equal parts. Two were stimulated with C1R-A33 cells loaded with the corresponding peptide and the other two were C1R-A33 cells loaded with the negative control HIV peptide. After 18 hours, supernatants were collected and tested for their IFN- ⁇ producing activity.
- Figure 5 shows a representative example of four patients. IFN- ⁇ production (50 pg / ml) against HIV peptide was subtracted as background. PBMCs from cancer patients stimulated with these three peptides recognized HLA-A33 transfect C1R cells loaded with the corresponding peptide in most cases and produced significant amounts of IFN- ⁇ ( Figure 5). In contrast, PBMCs from 5 HDs did not produce significant amounts of IFN- ⁇ against them (data not shown).
- LC— 1 HLA— A3 3 IEX-1
- QG56 HLA—A33—IEX—1
- HGC27 HLA—A33—IEX— ⁇
- PBMC stimulated with IEX-1 derived peptides showed a significant level of cytotoxicity against HLA—A33 + IEX—1 + LC—1 tumor cells HLA—A33— Not shown for HGC27 or QG56 cells.
- IEX43-51 (negative control peptide) did not show specific CTL activity.
- This result indicates that IEX47-56, IEX61-69, and IEX65-73 are antigenic epitopes that can induce specific CTL in HLA-A33-restricted PBMC in patients with epithelial cancer! Suggests.
- anti-HLA class I W6Z32, IgG2a
- anti-HLA class II H—DR, IgG2a
- anti-CD8 Nu-Ts / c, IgG2a
- anti-CD4 Nu-Th / i, IgGl ) (20 ⁇ g / ml
- Anti-CD14 JML—H14, IgG2a
- mAb was used as a control.
- cytotoxicity of these peptide-stimulated PBMCs was not inhibited by anti-HLA class or anti-CD8 antibody in all cases tested by other mAbs (Fig. 7).
- the present invention relates to an HLA-restricted protein in which IEX-1 is isolated from T cells infiltrating gastric adenocarcinoma. And a tumor antigenic epitope recognized by a tumor-specific CTL.
- the present invention also discloses that IEX-1-derived antigenic peptide can induce HLA-restricted tumor-specific CTL in PBMC cultures of cancer patients.
- IEX-1 is also expressed in normal tissues, particularly heart, kidney, lung and PBL, these organs may be adverse events of specific immunotherapy with IEX-1-derived antigenic epitopes .
- the present invention does not limit the CTL induced by the 850-BCTL strain and the IEX-1-derived peptide, although both lyse HLA-A33 + tumor cells while an excess of the corresponding peptide is present in the culture. It was clarified that normal HLA-A33 + T cells were not damaged. In clinical trials using tumor antigen-derived peptide vaccines conducted by the inventors, serious adverse events have been observed even though some tumor antigens are widely expressed in normal tissues or organs. (Reference 47) Therefore, the above results suggest that the IEX-1-derived peptide of the present invention can be used as a peptide vaccine suitable for cancer treatment.
- HLA—A33 is one of the most common HLA—A alleles for Asians and blacks! 13% of Japanese, 14% of Koreans, 14% of whites, and 16% of blacks (References 14 and 15).
- IEX-1 is highly expressed in cancer tissues. Therefore, the antigenic peptide of the present invention will be widely available for specific immunotherapy for HLA-A33 + cancer patients.
- Reference 5 Mine, ⁇ ⁇ , Gouhara, R., Hida, ⁇ ⁇ , Imai, ⁇ ⁇ , Azuma, ⁇ ⁇ , Rikimaru, ⁇ ⁇ ,
- Literature ll Ito, M., Shichijo, S., Tsuda, ⁇ ⁇ , Ochi, M., Harashima, ⁇ ⁇ , Saito, ⁇ ⁇ , and Itoh, K. Molecular basis of T cell-mediated recognition of pancreatic cancer cells Cancer Res, 61: 2038-2046, 2001.
- Reference 13 Takedatsu, ⁇ ⁇ , Shichijo, S., Katagiri, ⁇ ⁇ , Sawamizu, ⁇ ⁇ , Sata, M., and Itoh, K. Identification of peptide vaccine candidates sharing among HLA— A3 +, — A11 +, — A31 +, — A33 + cancer patients. Clin Cancer Res, in press.
- Reference 30 Kondratyev, A. D., Chung, K. ⁇ , and Jung, M. ⁇ . Identification and characterization of a radiation— inducible glycosylated human early-response gene. Cancer Res, 56: 1498—1502, 1996.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005517705A JP4925033B2 (ja) | 2004-02-03 | 2005-02-02 | ストレス誘導抗アポトーシス分子(iex−1)由来ペプチド |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004026691 | 2004-02-03 | ||
JP2004-026691 | 2004-02-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005075646A1 true WO2005075646A1 (ja) | 2005-08-18 |
WO2005075646A8 WO2005075646A8 (ja) | 2005-10-06 |
Family
ID=34835864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/001508 WO2005075646A1 (ja) | 2004-02-03 | 2005-02-02 | ストレス誘導抗アポトーシス分子(iex−1)由来ペプチド |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4925033B2 (ja) |
WO (1) | WO2005075646A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2801367A1 (en) | 2007-09-18 | 2014-11-12 | Green Peptide Co., Ltd. | CTL inducer composition |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002016416A2 (en) * | 2000-08-22 | 2002-02-28 | The Brigham And Women's Hospital, Inc. | Diagnosis and treatment of cardiovascular conditions |
WO2003012086A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
JP2004000216A (ja) * | 2002-04-26 | 2004-01-08 | Kyogo Ito | 腫瘍抗原 |
-
2005
- 2005-02-02 WO PCT/JP2005/001508 patent/WO2005075646A1/ja active Application Filing
- 2005-02-02 JP JP2005517705A patent/JP4925033B2/ja not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002016416A2 (en) * | 2000-08-22 | 2002-02-28 | The Brigham And Women's Hospital, Inc. | Diagnosis and treatment of cardiovascular conditions |
WO2003012086A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
JP2004000216A (ja) * | 2002-04-26 | 2004-01-08 | Kyogo Ito | 腫瘍抗原 |
Non-Patent Citations (4)
Title |
---|
MINE T. ET AL: "Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients.", CANCER SCI., vol. 94, no. 6, 2003, pages 548 - 556, XP002273942 * |
RECOGNITION OF AN ANTIGENIC PEPTIDE DERIVED FROM TYROSINASE-RELATED PROTEIN-2 BY CTL IN THE CONTEXT OF HLA-A31 AND -A33., J.IMMUNOL, vol. 160, no. 2, 1998, pages 890 - 897, XP002309396 * |
SASADA T. ET AL: "Immediate Early Response Gene X-1, a Stress-Inducible Antiapoptotic Gene, Encodes Cytotoxic T-Lymphocyte (CTL) Epitopes Capable of Inducing Human Leukocyte Antigen-A33-Restricted and Tumor-Reactive CTLs in Gastric Cancer Patients.", CANCER RES., vol. 64, April 2004 (2004-04-01), pages 2882 - 2888, XP002989506 * |
WU MX ET AL: "Roles of the stress-induced gene IEX-1 in regulation of cell death and oncogenesis.", APOPTOSIS, vol. 8, no. 1, 2003, pages 11 - 18, XP002989505 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2801367A1 (en) | 2007-09-18 | 2014-11-12 | Green Peptide Co., Ltd. | CTL inducer composition |
US9102715B2 (en) | 2007-09-18 | 2015-08-11 | Green Peptide Co., Ltd. | CTL inducer composition |
EP3156061A1 (en) | 2007-09-18 | 2017-04-19 | Green Peptide Co., Ltd. | Ctl inducer composition |
US9642900B2 (en) | 2007-09-18 | 2017-05-09 | Green Peptide Co., Ltd. | CTL inducer composition |
EP3494981A1 (en) | 2007-09-18 | 2019-06-12 | BrightPath Biotherapeutics Co., Ltd. | Ctl inducer composition |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005075646A1 (ja) | 2007-10-11 |
JP4925033B2 (ja) | 2012-04-25 |
WO2005075646A8 (ja) | 2005-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI228128B (en) | Tumor antigenic peptides derived from cyclophilin B | |
RU2435782C2 (ru) | Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция | |
US7432354B2 (en) | Tumor antigen | |
KR101610353B1 (ko) | Cdca1 펩티드 및 이를 포함하는 약학적 조성물 | |
KR101561175B1 (ko) | Cdh3 펩티드 및 이를 포함하는 의약제 | |
WO2005045027A1 (ja) | Wt1由来のhla−dr結合性抗原ペプチド | |
WO2007018199A1 (ja) | HLA-A2陽性者用glypican-3(GPC3)由来癌拒絶抗原ペプチド及びこれを含む医薬 | |
AU1350499A (en) | Tumor antigen peptide derivatives | |
WO2005068632A1 (ja) | HLA−A2402拘束性Ep−CAM特異的CTLが認識するエピトープ・ペプチド及びその用途 | |
JP6255594B2 (ja) | Th1細胞のLY6Kエピトープペプチドおよびこれを含有するワクチン | |
KR20110134482A (ko) | Sox2 유래의 hla-a24결합성 암 항원 펩티드 | |
JP2002284797A (ja) | サバイビン由来癌抗原ペプチド | |
JP4925033B2 (ja) | ストレス誘導抗アポトーシス分子(iex−1)由来ペプチド | |
US6664232B1 (en) | HLA-A2 restraint tumor antigen peptide originating in SART-1 | |
JPWO2003037917A1 (ja) | 腫瘍抗原 | |
Gene et al. | Immediate Early Response Gene X-1, a Stress-Inducible | |
KR20010071848A (ko) | Sart-1 유래의 종양 항원 펩티드 | |
WO2007013352A1 (ja) | Hla-a24分子結合性副甲状腺ホルモン関連蛋白由来ペプチドを含有する医薬組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WR | Later publication of a revised version of an international search report | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005517705 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |